Brief: Mabpharm Says NMPA Approved Clinical Trial Application Of CMAB807X To Treat Tumor Bone Metastasis
13/01/2022 13:02
Jan 13 (Reuters) - Mabpharm Ltd 2181.HK :
* NMPA OF PRC APPROVED CLINICAL TRIAL APPLICATION OF
CMAB807X FOR
TREATMENT OF TUMOR BONE METASTASIS
Further company coverage: 2181.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mabpharm
See all newsBrief: Mabpharm Says NMPA Approves CMAB807X (Denosumab Injection) NDA
Brief: Mabpharm Says NMPA Approves Cmab807 (Denosumab Injection) NDA
Brief: Mabpharm FY Profit And Total Comprehensive Income Attributable Rmb57.1 Million
Brief: Mabpharm Says Approval From Drug Regulatory Authority Of Pakistan On Registration Of Core Product,CMAB008
Brief: Mabpharm Says Approval From Indonesian National Agency Of Drug And Food Control Of CMAB008